Detailed narrative
Surgical franchise and the Unity VCS launch cycle
Surgical revenue rose 5% to $1.4B, led by equipment up 13% to $243M as Unity VCS ramped. Management is deliberately pacing installations to embed training, clinical support and workflow integration so sites realize the promised efficiency of 4D Phaco technology, which moves the tip in a multidirectional pattern to remove the lens with less energy.
Time-and-motion studies presented at AAO showed statistically significant efficiency gains versus legacy systems, letting surgeons perform more procedures per day. The standalone cataract version, Unity CS, is being readied for wide availability in the coming months⏳, and management expects equipment to accelerate further in 2026, though it declined to commit to a specific percentage.
Implantables and intensifying IOL competition
Implantable sales grew only 2% to $432M in an increasingly competitive market. PanOptix Pro — offering 94% light utilization and half the light scatter of its predecessor — is beginning to stabilize US trifocal IOL share, with reception strong enough that consignment inventory ran short and some Japan shipments were delayed.
Management expects the next couple of years to be difficult competitively as many entrants arrive, but sees offsets in rising AT-IOL penetration (up 130 bps this quarter), Alcon's majority share of the US AT-IOL market, and an ongoing global rollout of PanOptix Pro (Europe not until 2026) plus Vivity on Clareon material in Europe.
Alcon reported growing share in toric and monofocal IOLs globally.
Vision Care: contact lenses and the pricing dynamic
Contact lens sales grew 5% to $707M, driven by product innovation and price increases, with toric modalities up double-digit on the proprietary 8-and-4 design that expands access for the >40% of patients who are astigmatic. Growth was partly offset by declines in legacy DAILIES AquaComfort Plus, where promotional activity has been limited.
The US market grew ~6% but management flagged heavy price rebating to consumers, while international lagged (Japan flat-to-negative, Europe soft) on thin new-product flow. The DACP-to-Precision/DAILIES Total 1 mix shift benefits gross margin more than share, and US DAILIES share remains challenged by price competition.
Ocular health and the Tryptyr launch
Ocular health grew 6% to $462M, led by dry-eye and glaucoma drops including Systane (high-single-digit growth), Rocklatan and initial Tryptyr sales, partly pressured by the divestment of certain eye drops to Ocumension in China (to be lapped in Q4). Tryptyr, launched in August, is the first prescription drop that stimulates natural tear production as early as day 1, addressing the core mechanism of dry-eye disease.
Early trial and prescribing breadth across ophthalmologists and optometrists is ahead of expectations. Management cautioned that audited IQVIA TRx data understates the ramp because most scripts flow through a digital pharmacy platform (BlinkRx) that is not captured in audited sources.
Tariffs, margins and capital returns
Core gross margin declined 50 bps to 62.9% and core operating margin fell 60 bps to 20.2%, driven by incremental tariffs, new-product launch spend and higher R&D. Alcon incurred $57M of tariff charges in the first nine months ($38M in COGS, $19M capitalized on the balance sheet), and expects a step-up in Q4 with a full-year COGS impact of ~$100M, offset primarily by FX and operational actions.
Robust cash generation funded $550M of capital returns in nine months ($384M buyback, $166M dividends), though free cash flow of $1.2B trailed the prior year's $1.3B on higher capex.
End-market dynamics: cataract and contact-lens markets
Global cataract procedure volumes grew ~3% in the quarter — an improvement from a flat US in the prior quarter but still below the historical ~4% global / ~3% US trend management expects to revert to, citing too many untreated cataracts against a shrinking surgeon base and a productivity pause it attributes variously to staffing, generational practice turnover and private-equity dynamics.
Global AT-IOL penetration rose 130 bps. The global contact-lens market grew ~4% (moving-annual-total ~5%), with a strong US partly offset by weak international; management attributes softer market growth largely to lighter industry price increases in 2025 after heavy COVID-era inflation, and finds little correlation with consumer stretching of lenses.
STAAR Surgical acquisition and refractive/glaucoma strategy
Management reiterated support for its proposed acquisition of STAAR Surgical ahead of a shareholder vote and go-shop period, valuing STAAR's proven columnar-material ICL as complementary to Alcon's refractive laser business and citing an attractive premium — while stressing the deal is not essential to long-term growth.
On glaucoma, Alcon consolidated its in-theater sales force to sell both IOLs and Hydrus, and is building an expanded clinic-facing team for Voyager and Valeda to pursue glaucoma specialists (SLT) and retina (AMD), signaling expansion, not retreat, in interventional glaucoma.
In refractive, WaveLight Plus ray-tracing LASIK outperformed SMILE Pro in a head-to-head study.